The author of the report analyzed that the United States Prenatal Diagnostic Market accounted for US$ 527.5 million in 2017. The current focus in prenatal genetic testing and evaluation is on the identification of pathological conditions associated with clinically defined diseases caused by sequence variation in genomic DNA. Prenatal diagnostic procedures have been developed to detect birth defects in utero.

Pune, India -- (SBWire) -- 05/15/2018 --Prenatal diagnostics is used for testing the fetus before birth to determine certain hereditary disorders, for instance, Down's syndrome, hereditary sicknesses, chromosome abnormalities, neural tube defects, and other conditions. If high-risk is identified with the birth of a child, it can be assisted by conducting hereditary testing, common testing, and screening. The United States prenatal diagnostic market was valued at USD 527.5 Mn in 2017 and is expected to reach US$ 1,429.5 Mn by 2022.

Prenatal Diagnostic Market by Test Type (Prenatest, Verify, Visibility, Harmony, InformaSeq, MaterniT21 PLUS, NIFTY, Panorama, Others); by End-Use (Hospitals, Clinics, Others) – United States Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2018-2026 .

Get Sample Report @ https://www.absolutemarketsinsights.com/request_sample.php?id=17

The author of the report analyzed that the United States Prenatal Diagnostic Market accounted for US$ 527.5 million in 2017. The current focus in prenatal genetic testing and evaluation is on the identification of pathological conditions associated with clinically defined diseases caused by sequence variation in genomic DNA. Prenatal diagnostic procedures have been developed to detect birth defects in utero.

The report provides both, subjective and quantitative research of the market, as well as integrates worthy insights into the rational scenario and favored development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and detailed insights on the competitiveness of these players. The key business strategies such as M&A, affiliations, collaborations, and contracts adopted by the major players are also recognized and analyzed in the United States prenatal diagnostic market report.

MaterniT21 PLUS Anticipated to be the Dominant Segment During the Forecast Period, 2018-2026
MaterniT21 PLUS is a non-invasive test which requires only a blood sample, and can be performed as early as 9 weeks' gestation. It detects chromosomal abnormalities for chromosomes 21, 18, 13 in singleton and higher order multiple pregnancies, as well as fetal gender. It is the most technologically advanced non-invasive prenatal test commercially available for detecting fetal chromosomal abnormalities and holds the largest market share in U.S.

NIPT Screening Technologies to Drive the Market in United States
The rapid integration of NIPT into routine prenatal care is encouraging major ethical concerns on the responsible implementation and process of informed decision-making. MaterniT21 PLUS emerged as first NIPT and was introduced in October 2011. It is expected to have far-reaching impact on the delivery of optimized prenatal care, with the best possible outcome for both mother and baby.

For More Information @ https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=17

United States Prenatal Diagnostic is Fragmented with the Presence of Regional Players
United States Prenatal Diagnostic market are Laboratory Corporation of America Holdings, Eurofins NTD, LLC, Abbott Laboratories, Hologic Inc., Illumina, Inc., Natera, Inc., PerkinElmer, Inc., Sequenom, Inc., Ariosa Diagnostics, Inc., and Ravgen. Inc. amongst others.

Illumina, Inc. and Natera, Inc. entered into a three-year agreement whereby Illumina supplied Natera with the HiSeq 2500 sequencing system and associated consumables for performing the non-invasive prenatal test (NIPT) Panorama. Illumina is completely focused enabling the rapid growth of NIPT and the broader reproductive health market with technology, products, and FDA-approved in vitro diagnostic systems.

Purchase the complete report @ https://www.absolutemarketsinsights.com/checkout?id=17

Prenatal Diagnostic Market – By Type
Prenatest, Verify
Visibility
Harmony
InformaSeq
MaterniT21 PLUS
NIFTY
Panorama
Others)

Prenatal Diagnostic Market – By End-Use
Hospitals
Clinics
Others